A real-world economic analysis of biologic therapies for psoriatic arthritis in Italy: results of the CHRONOS observational longitudinal study

Table 1 Number of patients considered in cost-per-response and cost-per-sustained response analyses according to response criteria

Response criterion	Cost-per -response analyses		Cost-per-sustained response analysis
Response criterion	Patients evaluable at 6 months (N)	Patients evaluable at 12 months (N)	Patients evaluable at 6 months and 12 months (N)
DAS28	307	296	271
ACR20	194	189	NE
ACR50	194	191	NE

ACR College of Rheumatology response, DAS28 Disease Activity Score 28 joints, NE Not evaluated

ISSN: 1472-6963